Citadel Advisors’s Repare Therapeutics RPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-900
| Closed | -$887 | – | 14696 |
|
|
2025
Q1 | $887 | Buy |
+900
| New | +$1.08K | ﹤0.01% | 14201 |
|
|
2024
Q4 | – | Sell |
-300
| Closed | -$1.03K | – | 15252 |
|
|
2024
Q3 | $1.03K | Sell |
300
-1,100
| -79% | -$3.62K | ﹤0.01% | 13918 |
|
|
2024
Q2 | $4.62K | Sell |
1,400
-1,300
| -48% | -$4.64K | ﹤0.01% | 13464 |
|
|
2024
Q1 | $12.7K | Sell |
2,700
-7,500
| -74% | -$48K | ﹤0.01% | 13348 |
|
|
2023
Q4 | $74.5K | Buy |
10,200
+3,400
| +50% | +$19K | ﹤0.01% | 11313 |
|
|
2023
Q3 | $82.1K | Buy |
6,800
+4,700
| +224% | +$48.5K | ﹤0.01% | 11142 |
|
|
2023
Q2 | $22.2K | Sell |
2,100
-1,300
| -38% | -$13.4K | ﹤0.01% | 12634 |
|
|
2023
Q1 | $33.5K | Buy |
3,400
+2,200
| +183% | +$25.2K | ﹤0.01% | 12623 |
|
|
2022
Q4 | $17.7K | Buy |
+1,200
| New | +$17.9K | ﹤0.01% | 13235 |
|
|
2022
Q3 | – | Sell |
-21,700
| Closed | -$304K | – | 13472 |
|
|
2022
Q2 | $304K | Buy |
+21,700
| New | +$256K | ﹤0.01% | 9776 |
|
Citadel Advisors's RPTX Position: Q1 2026 in Review
Citadel Advisors sold out of Repare Therapeutics (RPTX) in Q1 2026, closing a stake of 238,912 shares — an estimated $621K sold.
Citadel Advisors first reported a position in RPTX in Q2 2020 and held it in 22 quarters. The position peaked at $6.76M in Q2 2021. 0 funds tracked by Wall St. Rank hold RPTX as of Q1 2026.
- Citadel Advisors reported no remaining Repare Therapeutics position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 238,912 Repare Therapeutics shares in Q1 2026, an estimated $621K.
- Citadel Advisors first reported a position in Repare Therapeutics in Q2 2020 and held it in 22 quarters.
- Citadel Advisors's Repare Therapeutics position peaked at $6.76M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Repare Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.